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ABSTRACT 
Non-aqueous oil-in-oil solvent evaporation technique is used for the preparation of polycaprolactone microspheres loaded with the antibiotic 
metronidazole by introducing different masses for the drug. The prepared microspheres are characterized by calculating drug encapsulation and 
drug loading percentages, measuring the corresponding particle size, performing FT-IR polymer-drug compatibility study and in vitro drug 
release. Moderate drug encapsulation values with a maximum of 34% are observed due to the low molecular weight of the drug. Microspheres 
had a particle size ranging between 130 and 280 µm with a spherical profile and porous structure. FT-IR study showed no interactions between 
the drug and the polymer. Drug release studies showed fast release rates for all the formulations with the slowest release for the highest drug 
loading.  
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INTRODUCTION 
Targeted drug delivery is a not a new concept in therapy, it 
dates back to 1906. The challenge is to create a medicine that 
targets only specific sites in the human body. This drug must 
be effective, and carried to the specific site without avoiding 
the immunogenic system 1-4. Using biodegradable and 
biocompatible polymers in targeted drug delivery has many 
advantages such as providing sustained delivery of the drug, 
its localized delivery and its stability. Different kinds of drugs 
can be encapsulated in various types of polymers depending 
on their chemical and physical characteristics. One of the 
most common techniques used for microencapsulation is the 
solvent evaporation used for both hydrophobic and 
hydrophilic drugs. It has many advantages because it 
requires only simple experimental conditions like heat and 
stirring 5, 6. 
Metronidazole (MTZ) is an antibiotic used against anaerobic 
bacteria and certain parasites. Metronidazole has a broad 
spectrum of protozoal and antimicrobial activity, both locally 
and synthetically 7. Treatment using MTZ could induce some 
reported side effects such as epigastric pain, mouth dryness, 
nausea and others. In order to decrease these adverse 
effects, in addition to deliver the drug to the site of infection 
for a longer period and reach the best antibiotic efficiency, 
MTZ polymeric microspheres could be formulated8. 
Polycaprolactone (PCL) belongs to the family of polyesters. It 
is highly miscible in organic solvents. In addition, it adheres 
well to a large number of surfaces, which enabled it to be 
used widely in several medical applications 9-11. PCL is 
nontoxic and semicrystalline with high organic solvent 
solubility. Due to the polymer very low degradation rate and 
high drug permeability, it has been extensively used in the 
medical field in implant devices in tissue engineering and in 
drug delivery devices 12, 13. 
In this study, MTZ microspheres formulations are prepared 
using non-aqueous o/o emulsion solvent evaporation 
technique with PCL as the coating polymer. Microspheres are 
then characterized for drug loading, drug encapsulation, 
particle size, drug-polymer interaction and in vitro drug 
release. 
EXPERIMENTAL 
Materials used include the polymer, Poly-ɛ-caprolactone 
(average MW 80,000), the drug Metronidazole, the 
surfactant Span 80, and Phosphate Buffered Saline (PBS) (0.2 
M, pH 7.4). They are purchased from Sigma-Aldrich, Chemie, 
Germany. Paraffin Oil, dichloromethane (DCM), Methanol 
(MeOH) and n-hexane are of analytical grade. 
Method description: non-aqueous oil-in-oil (o/o) solvent 
evaporation technique is used for the formulation of MTZ 
microspheres. Several formulations were prepared by fixing 
the PCL mass to 500 mg and changing drug masses between 
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50 and 200 mg. The polymer and the drug are dissolved in a 
mixture of DCM/MeOH forming the first organic phase. The 
mixture is then added into a second organic phase formed of 
250 ml Paraffin oil containing 1% surfactant Span 80. After 
mixing the solution for 6 hours using a mechanical stirrer 
(MSP-1 Digital Overhead Stirrer, Jeiotech, Korea) to allow the 
solvent evaporation and microencapsulation of the drug, 
microspheres are recuperated by filtration after washing 
with hexane and few drops of methanol. Microspheres are 
then dried for 48 hrs at 40°C. 
Characterization: 
1- Drug encapsulation (%DE) and Drug Loading 
(%DL): microspheres are dissolved in 10 ml 
DCM/MeOH (7/3) and the drug content of each 
formulation is measured using UV/Vis 
spectrophotometer (Epoch Bioteck, USA) at 311 nm and 
calculated as follows:  
 
%DE = 
                         
                       
*100 
 
%DL = 
                         
                   
 *100 
 
2- Particle size: Laser Diffraction Granulometer 
(LA950V2, Horiba Ltd., France) is used to determine the 
size of microspheres. A quantity of microspheres is 
suspended in water, with few drops of Tween 80 for 
better dispersion. The average particle size is measured 
in micrometers. 
3- Fourier Transform-Infrared study (FT-IR): FT-IR 
spectra of PCL blank microspheres, MTZ pure drug and 
PCL MTZ-loaded microspheres are recorded on FT-IR 
spectrometer (Frontier, Perkin Elmer, USA) in order to 
investigate the possible chemical interactions between 
the drug and the blend matrix. 
4- In vitro drug release study: in vitro release study is 
carried out in PBS solution (0.2 M, pH 7.4). 25 mg 
microspheres are introduced in dialysis bags having a 
molecular weight cut off of 12000-14000. These were 
suspended in 15 ml PBS at 37°C. At different time 
intervals, 1 ml of the release medium is withdrawn and 
replaced with fresh solution and tested for its drug 
content at 311 nm. 
RESULTS AND DISCUSSION 
Non-aqueous solvent evaporation method was applied for 
the preparation of MTZ-loaded PCL microspheres. Since MTZ 
is water soluble, the oil-in-oil method was chosen. It consists 
of adding the organic active phase containing the drug into 
another organic phase containing the hydrophobic 
surfactant Span 80. This method is preferred in the case of 
MTZ in order to avoid the loss of drug during 
microencapsulation step and improve drug encapsulation 
and bioavailability compared to hydrophobic drugs where an 
aqueous phase is used instead 14. 
Morphology of microspheres: 
SEM microphotographs of the prepared samples showed a 
homogeneous reproducible spherical profile with a porous 
structure of the polymeric matrix (Figure 1). 
 
Figure 1: SEM microphotographs of microspheres at 
500x magnifications 
 
Drug content and size of microspheres: 
Microspheres formulations were prepared by changing the 
drug mass between 50 and 200 mg. For each mass, %DE and 
%DL were calculated along with the average particle size. 
Results are presented in Table 1.  
  
 Table 1: %DE, %DL and particle size of the different prepared formulations 
Formulation Code 
Drug 
Introduced 
(mg) 
% DE % DL Size (µm) 
M1 50 13 0.26 280 
M2 75 14 0.4 131 
M3 100 34 1.5 142 
M4 150 24 1.4 165 
M5 200 11 0.9 242 
 
PCL microspheres loaded with MTZ had a particle size 
ranging between 131 and 280 µm (Table 1). In comparison 
to other drugs encapsulated in PCL such as Amphotericin B, 
and prepared using an aqueous phase and a hydrophilic 
surfactant, microspheres had a particle size ranging between 
110 µm and 125 µm11. This difference could be attributed to 
the fact that the organic solvent DCM used in preparing MTZ 
microspheres has a higher solubility in Paraffin oil than in 
water. This leads to a faster mass transfer between the two 
dispersed and continuous phases, leading to rapid 
precipitation of microspheres and thus larger particles 15, 16. 
Concerning the drug content of microspheres, the maximum 
%DE and % DL were 34% and 1.5% respectively. They were 
attributed to formulation M3 containing 100 mg drug.  Drug 
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molecular weight may have an effect on %DE and %DL. 
Drugs with low and average molecular weights easily diffuse 
out of the porous polymeric matrix 17.  
 
(a) 
 
 
(b) 
Figure 2: (a) Metronidazole (MTZ), C6H9N3O3,  
               (b) Polycaprolactone (PCL),(C6H10O1)n 
In the case of Metronidazole, it has a low molecular weight, 
which is about 171 g/mol. Thus, diffusion out of the 
microspheres could have occurred yielding low %DE and 
%DL 18, 19. 
Drug-polymer compatibility study: 
FT-IR study could confirm the chemical stability of MTZ 
encapsulated in PCL microspheres. This is done by 
measuring the characteristic peak shifts of the loaded 
microspheres in comparison with these of pure drug MTZ 
and polymer PCL. Recorded spectra are presented in Figure 
3.
 
 
Figure 3: FT-IR spectra of MTZ (a), PCL (b) and PCL MTZ-loaded microspheres (c) 
 
MTZ characteristic peaks are showing at 3220 cm-1 and 
assigned to stretching –OH, 3099 cm-1 to stretching =CH, 
1073 cm-1 to stretching –C-O  of –C-OH (Figure 3a) 20. 
Important bands are also showing in the spectrum of PCL 
(Figure 3b). Peak at 2943 cm-1 is assigned to stretching of –C-
H bending alkane. The peak at 1721 cm-1 corresponds to 
stretching of –C=O carbonyl21. 
The representative peaks of MTZ and PCL didn’t show any 
significant shifting and are present in the spectrum of loaded 
microspheres (Figure 3c). This indicated that the 
microencapsulation process didn’t change the chemical 
structure of the drug and there were no chemical 
interactions observed between the drug and the polymer.  
In vitro release study: 
Figure 4 shows the In vitro release profiles of the different 
formulations prepared. The study reveals that the release 
rate is fast for all the formulations and requires minutes to 
go to completion. This could be explained by the fact that the 
drug MTZ used is water soluble.  It has a good affinity 
towards the PBS release medium, and thus it tends to escape 
easily and be diffused out of the porous polymeric matrix 
within a short time 22. In addition, the sample containing 100 
mg drug, which is characterized by the highest %DL, has the 
slowest release rate and required 80 minutes to get 
completely released. 
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Figure 4: In Vitro release profile of MTZ prepared formulations 
 
Figure 5 show that the release rate becomes slower with the 
increase in drug content. In fact, at higher loadings, the 
chances of drug particles inside the polymer matrix to 
contact each other are high. This causes the formation of 
aggregates that need more time to dissolve, and thus more 
time for the drug to be released 23.  
 
Figure 5: Variation of release time with %DL of MTZ 
prepared formulations 
CONCLUSION 
The non-aqueous o/o solvent evaporation method was used 
to prepare metronidazole-loaded Polycaprolactone 
microspheres. Moderate drug encapsulation values with a 
maximum of 34% are observed. Microspheres had a particle 
size ranging between 130 and 280 µm with a spherical 
profile and porous structure. FT-IR study showed no 
interactions between the drug and the polymer. Drug release 
studies showed fast release rates for all the formulations 
with the slowest release for the highest drug loading.  
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